“The #1 Tech Opportunity of the Decade”

On February 8th, Luke Lango is making his biggest call of 2023. He’s recommending technology (that you’ve likely never heard of) that could help 122 million people… And mint up to $3 trillion in wealth.

Wed, February 8 at 8:00PM ET

SRNGU Stock: 12 Things to Know About a Potential Ginkgo Bioworks SPAC Merger

Boston biotech outfit Ginkgo Bioworks could be seeing a merger in the near future. The company, which deals in bio projects from food engineering to DNA reproduction to cannabinoid studies, is rumored to be looking into going public. The company that is apparently making the offer is Soaring Eagle Acquisitions (NASDAQ:SRNGU), a SPAC with a lengthy track record of successful mergers. The news is exciting investors and causing movement in SRNGU stock today.

a visualization of DNA in a vial

Source: Connect world / Shutterstock.com

The news might seem like just another SPAC story, but investors should take interest in this potential partnership.

The impressive portfolio behind Soaring Eagle and the huge biotech innovations of Ginkgo Bioworks could make this a very lucrative public offering. Here is everything you need to know:

SRNGU Stock and a Ginkgo Bioworks SPAC Merger

  • Harry Sloan and Jeff Sagansky head Soaring Eagle.
  • The two are best known for their SPAC deals with current hot stocks Skillz (NYSE:SKLZ) and DraftKings (NASDAQ:DKNG).
  • Soaring Eagle’s IPO was last month, and the company reeled in over $1.7 billion in proceeds.
  • Ginkgo is in innovative bio-engineering group found in 2009.
  • The company operates under several different businesses, and started as a DNA replication company.
  • After becoming widely successful in this operation, the company has expanded into different health sectors.
  • Segments spawned from the Ginkgo umbrella include plant-based food engineering, fertilizer production, and more recently, novel coronavirus testing technologies.
  • The company is rapidly increasing in notoriety because of its crucial new project. The company produces the RNA all major mRNA Covid-19 vaccine manufacturers use in their doses.

On the date of publication, Brenden Rearick did not have (either directly or indirectly) any positions in the securities mentioned in this article.

Article printed from InvestorPlace Media, https://investorplace.com/2021/04/srngu-stock-12-things-to-know-about-a-potential-ginkgo-bioworks-spac-merger/.

©2023 InvestorPlace Media, LLC